(NASDAQ: NPCE) Neuropace's forecast annual revenue growth rate of 12.33% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Neuropace's revenue in 2025 is $88,570,000.On average, 10 Wall Street analysts forecast NPCE's revenue for 2025 to be $3,228,324,145, with the lowest NPCE revenue forecast at $3,047,467,596, and the highest NPCE revenue forecast at $3,384,237,245. On average, 10 Wall Street analysts forecast NPCE's revenue for 2026 to be $3,424,265,858, with the lowest NPCE revenue forecast at $3,177,147,068, and the highest NPCE revenue forecast at $3,698,180,661.
In 2027, NPCE is forecast to generate $4,286,700,511 in revenue, with the lowest revenue forecast at $3,825,544,429 and the highest revenue forecast at $4,816,004,479.